Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H16FN3 |
| Molecular Weight | 281.3274 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=NC(N)=NC(=C1)C2=CC=C(F)C3=CC=CC=C23
InChI
InChIKey=ZZZQXCUPAJFVBN-UHFFFAOYSA-N
InChI=1S/C17H16FN3/c1-10(2)15-9-16(21-17(19)20-15)13-7-8-14(18)12-6-4-3-5-11(12)13/h3-10H,1-2H3,(H2,19,20,21)
| Molecular Formula | C17H16FN3 |
| Molecular Weight | 281.3274 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10455251 | https://www.ncbi.nlm.nih.gov/pubmed/16517693Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11575715
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10455251 | https://www.ncbi.nlm.nih.gov/pubmed/16517693
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11575715
RS-127445 is a selective; high affinity; orally bioavailable serotonin 5-HT2B receptor antagonist. RS-127445 was found to have a nanomolar affinity for the 5-HT2B receptor (pKi = 9.5 /-0.1) and 1,000 fold selectivity for this receptor as compared to numerous other receptors and ion channel binding sites. RS-127445 potently antagonized 5-HT-evoked formation of inositol phosphates (pK(B) = 9.5 /-0.1) and 5-HT-evoked increases in intracellular calcium (pIC50 = 10.4 /-0.1). RS-127445 also blocked 5-HT-evoked contraction of rat isolated stomach fundus (pA2 = 9.5 /-1.1) and ( /-)alpha-methyl-5-HT-mediated relaxation of the rat jugular vein (pA2 = 9.9 /-0.3). RS-127445 (MT-500) was being developed for the prophylactic treatment of migraine. POZEN acquired MT-500 from Roche in November 1999 and assumed full responsibility for its development for migraine prophylaxis.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. | 2010-09-01 |
|
| Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. | 2009-11-23 |
|
| Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. | 2004-08 |
|
| Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat. | 2004-04 |
|
| Regulation of septo-hippocampal activity by 5-hydroxytryptamine(2C) receptors. | 2003-08 |
|
| RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. | 1999-07 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/ 19740115
Curator's Comment: Can aslo be used i.p. https://www.ncbi.nlm.nih.gov/pubmed/20003079
Rats: oral administration of a selective, high affinity 5-HT(2B)receptor antagonist, RS-127445, significantly inhibited visceral hypersensitivity provoked by restraint stress (35 to 74% inhibition at 1 to 10 mg kg(-1)).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10455251
RS-127445 (0.3-3nM) potently inhibited the 5-HT evoked increase in the formation of inositol phosphates in HEK-293 cells expressing the human 5-HT2B receptors, producing parallel rightward shifts in the concentration response curves of 5-HT.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:40 GMT 2025
by
admin
on
Mon Mar 31 18:05:40 GMT 2025
|
| Record UNII |
0JAU3P8OBM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
RS-127445
Created by
admin on Mon Mar 31 18:05:40 GMT 2025 , Edited by admin on Mon Mar 31 18:05:40 GMT 2025
|
PRIMARY | |||
|
199864-87-4
Created by
admin on Mon Mar 31 18:05:40 GMT 2025 , Edited by admin on Mon Mar 31 18:05:40 GMT 2025
|
PRIMARY | |||
|
196968
Created by
admin on Mon Mar 31 18:05:40 GMT 2025 , Edited by admin on Mon Mar 31 18:05:40 GMT 2025
|
PRIMARY | |||
|
DTXSID60941960
Created by
admin on Mon Mar 31 18:05:40 GMT 2025 , Edited by admin on Mon Mar 31 18:05:40 GMT 2025
|
PRIMARY | |||
|
0JAU3P8OBM
Created by
admin on Mon Mar 31 18:05:40 GMT 2025 , Edited by admin on Mon Mar 31 18:05:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
ANTAGONIST
Ki
|
||
|
|
TARGET -> INHIBITOR |
Increases of inositol phosphates and intracellular calcium concentration.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
In development for migraine prophylaxis
|